Almetec to be exposed to fiercer competition

Daiichi-Sankyo’s Almetec (olmesartan medoxomi), a selective AT1 subtype angiotensin II receptor antagonist, will not be stable in 2014, as a growing number of Korean pharmaceutical companies are poised to enter a 90 billion Almetec market here.

Currently, a great number of domestic drug manufacturers, including Ahngook, Samjin and Chong Kun Dang, obtained the first version of Almetec generic...